Alpenglow Biosciences and Mayo Clinic announced a collaboration to advance drug development and clinical diagnostics with Alpenglow's 3D spatial biology platform. Alpenglow's platform includes patented high-throughput 3D imaging, cloud-based bioinformatics pipelines, and AI-powered spatial analysis. The platform has the ability to digitize entire tissues down to sub-cellular resolution and generate unique insights on vast amounts of data with the assistance of artificial intelligence. The collaboration aims to unlock additional insights and expand offerings while driving innovation within the biopharma diagnostics space and the Advanced Diagnostics Laboratory.
The platform will be integrated with multi-omics approaches, including multiplex immunofluorescence and single cell sequencing, to predict response to therapy and patient prognosis using Mayo Clinic's unique biospecimen repositories. An abstract will be presented at the American Association for Cancer Research Annual Meeting 2023, which describes the application of Alpenglow's 3D spatial biology platform to analyze human lung cancer samples from patients treated with immunotherapy, revealing novel 3D spatial insights that the team aims to correlate with treatment response.
Current innovations in pathology have focused on digitization of 2D slides, automated slide scanning, and AI analysis of these thin digitized sections. Alpenglow Biosciences has built a leapfrog technology by cutting out slides entirely and going direct to digital with 3D imaging and AI-powered insights. The collaboration between Alpenglow and Mayo Clinic aims to solve the biggest problems facing pathology to accelerate drug development and advance clinical diagnostics.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!